What is RPRX's 12-month price target and RQD AI Jury consensus?

RPRX's 12-month base price target is $71.91 (range $54.55 to $84.85), backed by transparent SEC XBRL cash-flow, Form 4 insider, and CBOE options flow analysis.

Stock Ratings / Health Care / RPRX

GMAB (70) ONC (71) ZTS (68) TEVA (61) ⌘ Pro Terminal →

Royalty Pharma plc (Class A) (RPRX) — RQD Stock Rating Cockpit

Q: Should I buy, hold, or sell RPRX stock right now?

Royalty Pharma plc (Class A) (RPRX) currently earns a Roarable Rating of B+ (Buy — BUY) with 76/100 RQD Confidence. High-quality cash engine (steady margins, 7% return on capital) with steady institutional support.

$66.52 -0.98% NASDAQ • Live Quote vs Prior Daily Close (Synced Snapshot) EXT / AFTER-HRS: $66.56

Royalty Pharma plc (Class A) (RPRX) earns a Roarable Rating of B+ (Buy) with 76/100 RQD Confidence. High-quality cash engine (steady margins, 7% return on capital) with steady institutional support. The company’s underlying cash engine and institutional positioning keep the composite score in the Green Buy zone.

ROARABLE B+ • BUY Cap $38.63B

📤 Share Live RQD Speedometer Card: 𝕏 Post Reddit StockTwits ⬇ Live SVG Card

⚡ INSTANT AI QUANT PREVIEW • $0 FREE TIER Click Any Pre-Computed AI Quant Specialist Briefing on RPRX Below — or Connect Your Own ChatGPT / Claude

🤖 Mara Quenwick • AI Quant Lead (Click for Instant Brief) Is RPRX stock a Buy, Hold, or Sell right now according to Roarable's RQD model?

▼

As of 2026-11-03, Royalty Pharma plc (Class A) (NASDAQ: RPRX) is rated B+ (Buy / BUY) by Roarable's 5-pillar RQD engine with a composite confidence score of 76/100 at a spot price of $66.52 (-0.98% 1D, market cap $38.63B). Pillar breakdown: Fundamental Cash Engine 13/20, Institutional 13F & Options Flow 19/20, SEC Balance-Sheet Forensics 14/20, FRED Macro Regime Fit 16/20, and Executive Insider Alignment 14/20. Across 1015 tracked Health Care issuers, RPRX ranks #28 in composite RQD confidence.

✓ Pre-computed one-to-many AI Quant brief

🤖 Ellis Vennor • AI Peer & Flow Quant (Click for Instant Brief) How does RPRX compare to GMAB and ONC in the Health Care sector?

▼

Within the Health Care sector (Biotechnology: Pharmaceutical Preparations), RPRX carries a Roarable B+ (76/100 RQD), trailing P/E of 49.2x, gross margin of —, and ROIC of 7.0%. By comparison, GMAB (Genmab A/S ADS) holds a B- grade (70/100 RQD, P/E 32.8x, ROIC 9.9%, cap $35.61B) and ONC (BeOne Medicines Ltd.) posts a B- grade (71/100 RQD, P/E 147.2x, ROIC 10.5%, cap $42.11B). Among the 5-stock peer group, ZTS leads on earnings multiple (12.2x) while ZTS leads on capital efficiency (25.7% ROIC).

✓ Pre-computed one-to-many AI Quant brief

🤖 Gideon Ashmere • AI SEC 10-K Forensics (Click for Instant Brief) What are the biggest fundamental strengths and SEC risk factors for RPRX?

▼

Per RPRX's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001802768), Royalty Pharma plc (Class A) generated $2.38B in revenue (+5.1% YoY), $770.9M in net income, and $2.38B in free cash flow against $19.62B in total assets and $8.57B in total debt. Key quantitative strengths: Big institutional funds and options desks are actively positioning on the bullish side. Primary risk factors monitored: Priced at 49x earnings—high expectations leave less room for a lukewarm quarter. Institutional options positioning shows a 50% call / 50% put premium split.

✓ Pre-computed one-to-many AI Quant brief

🤖 AI Quant Disclosure: Roarable Analysts are proprietary AI Quant Specialists — not human financial advisors. Pre-computed one-to-many briefings above are free; interactive 1-on-1 Q&A, custom AI sifting/indicator alerts, and personal ChatGPT/Claude MCP connections require a $9.95/mo Pro account (currently waitlist-only).

INTERACTIVE SCENARIO DECK:

🛡️ Portfolio Crash X-Ray

EXT / AFTER-HRS: $66.56 (+0.06%)🧬 Cannibal Buyback (-1.80% YoY Shares)⚙️ Cash Engine: 13/20 (C) • 100.2% FCF Margin

Verify 90D Bucket Audit →

📊 Historical Track Record: Scores of 76/100 (B+) historically ranked in the Top 11% of excess returns over the next 90 days (+7.6% avg 90D alpha vs SPY • 70.0% hit rate).

Audit Bucket Track Record →

RQD QUANT TACHOMETERBUY • B+

2-of-3 JEV AI Jury Bullish

Cash

SEC

Whale

Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer

5-PILLAR SNOWFLAKE RADARRw B+ · Rk B

Each axis scored 0–20

12M PRICE TARGET CONE+8.1% Base Target

WHALE OPTIONS SNAPSHOT: — (No Active Options Snapshot on file for RPRX)Realized 20D OHLCV Swing Band: ±4.8%

Deterministic 5-Pillar Attribution (76/100 Composite)

🔍 WHY RPRX SCORES 76/100 (B+) — TOP 3 DRIVERS2 Bullish Pillars + #1 Risk Drag

▲ #1 Bullish Driver: Whale & Options Positioning+19/20 pts (25% of score)

20D Institutional Volume Accumulation (±4.8% realized swing band)

▲ #2 Bullish Driver: Macro Regime Fit+16/20 pts (21% of score)

FRED Regime × Technicals: 96% of 52W Range • RSI-14 at 72 (OVERBOUGHT (>70))

▼ #1 Drag / Risk Factor: Cash Engine Quality13/20 pts (-7 pt drag)

Capital intensity & 52% operating margin leave 7 pts on the table

📈 PAST 4 QUARTERS RQD vs SUBSEQUENT RETURNQ1 → Q2 → Q3 → Current

Q1 (-3Q)

Grade B-$58.99+5.4% Next Q

Q2 (-2Q)

Grade B$62.15+4.3% Next Q

Q3 (-1Q)

Grade B$64.82+2.6% Next Q

Current

Grade B+$66.52+7.6% Hist 90D α

Trajectory: B- (68) → B+ (76)Full Audit →

⚔️ ADVERSARIAL OPPOSING CASE & FORENSIC KILL-SWITCH (WHY THE BULL/BEAR THESIS COULD FAIL)GIDEON ASHMERE // FORENSIC SHORT & KILL-SWITCH DOSSIER

⚔️ Adversarial Opposing Case: Why the RPRX Bull Thesis Could Fail

Gideon Ashmere Forensic Desk →

Even with a 76/100 (B+) score, RPRX faces multiple-compression risk if 49.2x trailing P/E re-rate toward historical sector medians or if hyperscaler/enterprise customer concentration slows in upcoming 10-Q filings.

⚠️ Forensic Kill-Switch #1

Priced at 49x earnings—high expectations leave less room for a lukewarm quarter.

⚠️ Forensic Kill-Switch #2

Dilution & Margin Drag: Cannibal Buyback (-1.80% YoY Shares) — any gross margin slip below 49.5% triggers an automatic RQD downgrade.

⚠️ Forensic Kill-Switch #3

Technical & Forensic Kill-Switch: A daily close below the 50D SMA ($60.56) or 200D SMA ($53.63) invalidates the momentum regime and cuts Target Base ($71.91) toward Bear Floor ($54.55).

🎲 LIVE PREDICTION MARKET ODDS TIED TO $RPRX• $2.4M Crowd Pool • Kalshi / Polymarket Composite

Contract: “RPRX Beats Next Quarter EPS Consensus (Dec 30, 2026) & Holds Above 200D SMA”

YES 76%NO 24%Trade / Inspect Odds →

RSI-14 MOMENTUMOVERBOUGHT (>70)

7230 Oversold · 70 Hot

ALTMAN-Z SHIELDWATCH ZONE (1.8–3.0)

2.90>3.0 Fortress Safe

PIOTROSKI F-SCOREHIGH QUALITY (7–9)

8 / 99-Pt Accounting

52-WEEK LASER RANGE96% OF RANGE

L: $36$66.52H: $68

1. Money & Cash Health● MIXED

Are profits real cash in the bank?

Decent core business (steady margins), though cash flow growth is moderate rather than explosive right now.

Factor Grade: CRQD 13 / 20

2. Big Money & Insiders● BUYING

Are whales & executives buying or selling?

Hedge funds and options traders are leaning bullish, showing strong institutional appetite.

Factor Grade: A-RQD 33 / 40

3. Hidden Risks & Market Weather● ALL CLEAR

SEC fine-print scan & interest-rate fit

Clean SEC fine-print check with low hidden accounting risk and favorable interest-rate weather.

Factor Grade: BRQD 30 / 40

MULTI-MODEL JEV QUANT JURY DELIBERATION

2-of-3 JEV AI Jury Bullish on RPRX

Cash & Moat Bull AI

ROIC & Free Cash Flow Model

NEUTRAL (65)

7.0% ROIC with 42.0% gross margin and 6.29% FCF yield.

SEC Forensic Auditor AI

10-K Accruals & Altman-Z Guard

BULLISH (70)

Altman-Z 2.90 and Piotroski 8/9 pass balance-sheet audit.

Whale & Macro Hawk AI

Options Skew, 13F & Fed NetLiq

BULLISH (82)

33/40 institutional & smart-money positioning score with 16/20 macro alignment.

Bull Case: Why Buyers Like RPRX

✓Big institutional funds and options desks are actively positioning on the bullish side.
✓Company leadership has skin in the game with net positive insider conviction.

Bear Case: What Could Go Wrong

!Priced at 49x earnings—high expectations leave less room for a lukewarm quarter.

ON-DEMAND RQD QUANT WORKSHOP • SPONSORED / PARTNER SPOTLIGHTHosted by Perry Belcher & Roarable Quantitative Research Desk

Scheduled RQD Strong Buys & Whale Accumulation Briefing (RPRX Tape Review)

✓Breakdown of the highest-scoring RQD Green-Light breakouts across our 5,200+ rated universe
✓Forensic Red-Light accounting & dilution traps to review on your watchlist
✓Includes downloadable .ics calendar invite & nightly RQD rating-change email alerts

RQD INSIDER CLUB WAITLIST$49/YR PLANNED

Want Custom AI PineScript / Python Indicators & Priority Rating-Change Alerts?

Join Founding VIP Waitlist (No Card Required) →$100K Arena

RPRX // CANDLESTICK & AUTO-TRENDLINE WORKSTATION6M: +32.51%⚡ TESTING RESISTANCE

2026-11-03O $65.93H $67.18L $65.93C $66.52VOL 4.66M

RES: $67.97SUP: $54.62SMA50: $60.56SMA200: $53.63

PRIMARY-SOURCE FORENSICS, SECOND-ORDER LINKS & AI ANALYST DESK

RPRX Dilution Monitor, Expectations Hurdle, Butterfly Connections & Policy Exposure

🦋 RPRX Butterfly Map → + Track RPRX →

Share Count & Dilution Monitor

Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).

Reverse-DCF Expectations Hurdle

35.9%/yr Implied 5Y Growth

vs. +5.1% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).

Ellis Vennor Setup Ledger

No active Ellis Vennor swing setup published on RPRX today. View full Setup Ledger →

🦋 Documented & Second-Order Butterfly Connections Open Graph →

No direct multi-tier Butterfly edges indexed yet for RPRX. Explore sector supply chains on /butterfly.

AI Analyst Theses, Washington Policy & Company Video

🎬 No recent verified company-specific video clip queued for RPRX today (we never pad ticker pages with unrelated generic clips). Browse Macro Video Desk →

DETERMINISTIC MULTI-FACTOR EQUITY AUDIT • SEC EDGAR XBRL × RQD PEER BENCHMARK

📊 Quantitative Sector Peer Comparison, SEC Filing Delta & Investment FAQ (RPRX)

Health Care Rank #28 of 1015 ⚔️ GMAB vs RPRX Full Matrix →

1. Head-to-Head Health Care Peer Comparison (RPRX vs. GMAB, ONC, ZTS, TEVA)

Industry: Biotechnology: Pharmaceutical Preparations (489 Tracked Issuers)

Across 1015 tracked Health Care securities in the Roarable RQD universe, Royalty Pharma plc (Class A) (RPRX) ranks #28 by composite RQD confidence (76/100, grade B+) and #46 by equity capitalization ($38.63B). Within this direct 5-issuer industry benchmark cohort, ZTS leads on earnings valuation at 12.2x trailing P/E, while ZTS leads on capital efficiency and profitability with 25.7% ROIC and 71.8% gross margin. RPRX currently leads its immediate peer cohort in composite quantitative strength at 76/100 (B+).

Ticker / Company	Roarable Grade	RQD Score	Trailing P/E	Gross Margin	ROIC	1D Change	Market Cap	Head-to-Head
RPRX ACTIVE Royalty Pharma plc (Class A)	B+	76/100	49.2x	—	7.0%	-0.98%	$38.63B	Benchmark Subject
GMAB Genmab A/S ADS	B-	70/100	32.8x	—	9.9%	-3.75%	$35.61B	/gmab-vs-rprx →
ONC BeOne Medicines Ltd.	B-	71/100	147.2x	87.5%	10.5%	-2.45%	$42.11B	/onc-vs-rprx →
ZTS Zoetis Inc.	C+	68/100	12.2x	71.8%	25.7%	+4.34%	$32.94B	/zts-vs-rprx →
TEVA Teva Pharmaceutical Industries Limited	C-	61/100	34.3x	51.8%	9.4%	-3.30%	$49.05B	/teva-vs-rprx →

2. Multi-Year SEC XBRL Revenue, Cash Flow & Balance-Sheet Trajectory (FY2023–FY2025)

SEC EDGAR 10-K • FILED 2025-12-31 • CIK 0001802768 ↗

In its most recent audited fiscal period (FY2025, filed 2025-12-31), Royalty Pharma plc (Class A) (RPRX) reported GAAP revenue of $2.38B (+5.1% vs. FY2024 revenue of $2.26B , and +1.0% cumulative change since FY2023) , GAAP net income of $770.9M, operating cash flow of $2.49B, and free cash flow of $2.38B (-10.7% YoY). On the balance sheet, RPRX closed FY2025 with $19.62B in total assets against $8.57B in total debt (Altman Z-Score: 2.90, Piotroski F-Score: 8/9).

Fiscal Period	Filing Date	Revenue	Net Income	Operating Cash Flow	Free Cash Flow	Total Assets	Total Debt
FY2025 (FY)	2025-12-31	$2.38B	$770.9M	$2.49B	$2.38B	$19.62B	$8.57B
FY2024 (FY)	2024-12-31	$2.26B	$859.0M	$2.77B	$2.67B	$18.22B	$6.61B
FY2023 (FY)	2023-12-31	$2.35B	$1.13B	$2.99B	$2.88B	$20.85B	$4.88B

3. RPRX Data-Verified Investor FAQ (RQD Rating, Sector Peers, SEC Forensics & Technicals)

✓ SCHEMA.ORG FAQPAGE JSON-LD ENABLED

Is RPRX stock a Buy, Hold, or Sell right now according to Roarable's RQD model?

How does RPRX compare to GMAB and ONC in the Health Care sector?

What are the biggest fundamental strengths and SEC risk factors for RPRX?

Where is RPRX trading relative to its 50-day, 200-day, and 52-week technical levels?

RPRX last traded at $66.52 (-0.98% on volume of 2,873,558 shares), positioning the stock +9.84% above its 50-day simple moving average ($60.56) and +24.04% above its 200-day simple moving average ($53.63). Across its 52-week range of $36.03 to $67.71, RPRX sits at the 96.2% percentile with a 14-day RSI of 72.0 (OVERBOUGHT (>70)) and an implied next-earnings move of ±4.8% ($63.33 to $69.71).

Direct Sub-Reports: RPRX RQD Cockpit RPRX 12M Forecast RPRX Earnings & Move RPRX Dividends & DRIP RPRX Insiders & 13F RPRX Whale Options RPRX Profit Sankey RPRX News & Why

ROARABLE RATING BRIEF • RQD 76/100 (B+) ✓ SEC XBRL & RQD VERIFIED

RPRX — Royalty Pharma plc (Class A): What the Facts Mean to a Prospective Investor

Methodology: RQD v6.2 Deterministic 5-Pillar & SEC XBRL Audit

Updated: 2025-12-31

1. Roarable Rating Brief: What This Means to a Prospective Investor

Royalty Pharma plc (Class A) (RPRX) earns a live Roarable RQD composite score of 76/100, corresponding to a B+ letter grade (Roarable Buy) at a spot price of $66.52 (-0.98% 1D, market capitalization $38.63B).

Fundamental Cash Engine (13/20): Anchored by return on invested capital (ROIC) of 7.0%, gross margin of —, operating margin of 65.6%, and free cash flow yield of 6.29%.
Whale 13F & Options Flow (19/20) + Insider Conviction (14/20): Tracks institutional 13F accumulation, CBOE options call/put positioning, and SEC Form 4 / Congressional PTR filings.
Macro Regime Fit (16/20) + Forensic Balance Sheet (14/20): Incorporates a 0.94x equity beta, Altman Z-Score of 2.90, Piotroski F-Score of 8/9, and Debt/Equity of 0.88x.

2. Business Model, Unit Margins & SEC Financial Trajectory

Royalty Pharma plc (Class A Ordinary Shares, NASDAQ: RPRX) is classified in the Health Care sector and the Biotechnology: Pharmaceutical Preparations industry. It is a publicly traded US issuer with a market capitalization of $37.9B. Operating margin of 65.6% and net margin of 32.

In its latest audited SEC EDGAR 10-K filing for FY2025 (filed 2025-12-31), Royalty Pharma plc (Class A) (RPRX) reported $2.38B in annual revenue (up from $2.26B in FY2024, +5.1% YoY) and $770.9M in GAAP net income. Over the multi-year SEC filing window from FY2023 ($2.35B revenue, $1.13B net income) through FY2025, RPRX scaled operating cash flow to $2.49B and free cash flow to $2.38B, backed by $19.62B in total assets against $8.57B in total debt.

3. Institutional Bull vs. Bear Thesis & Valuation Tradeoff

🐂 Primary Bull Case (B+ • RQD 76/100): Big institutional funds and options desks are actively positioning on the bullish side. Company leadership has skin in the game with net positive insider conviction. With Fundamental Cash Engine at 13/20 and Institutional Whale Flow at 19/20, sustained execution supports upside toward the upper end of the $36.03 – $67.71 52-week range.
🐻 Primary Bear Case & Valuation Risk: Priced at 49x earnings—high expectations leave less room for a lukewarm quarter. Investors must weigh 49.2x trailing P/E and 27.8x EV/EBITDA against 65.6% operating margins and a 0.94x macro beta.

4. 2nd-Order Butterfly Ripples & Key Questions to Watch

Supply_chain is NONE and butterfly_links is empty. The graph does not identify upstream or downstream dependencies, sector correlations beyond the stated sector and industry, or second-order bottlenecks. A prospective investor should not infer supply-chain relationships from this data.

Key Question #1: Can RPRX sustain or expand its 65.6% operating margin and 7.0% ROIC against Biotechnology: Pharmaceutical Preparations peers over the next 4 quarters?
Key Question #2: Following FY2025 revenue of $2.38B and free cash flow of $2.38B, how will capital allocation balance growth reinvestment against $8.57B in total debt?
Key Question #3: How sensitive is RPRX's 45.8x forward P/E multiple to Health Care capital spending cycles and macro interest-rate shifts (Beta 0.94x)?

RPRX Live News Feed, Press Releases & Catalyst Wire

Real-time company headlines, analyst actions, and sector developments for Royalty Pharma plc (Class A) (RPRX) • Click "Debate This Headline" to argue it in the Roar Pit below

💬 Jump to RPRX Debate Forum (3) ↓

🟡 MARKET WIRE Yahoo Finance UK • 22h ago

Royalty Pharma plc (RPRX) stock price, news, quote and history

Yahoo Finance UK report covering Royalty Pharma plc (Class A) (RPRX) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🟡 MARKET WIRE The Motley Fool • 1d ago

Should You Buy Royalty Pharma Stock Before Nov. 4?

The Motley Fool report covering Royalty Pharma plc (Class A) (RPRX) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🟡 MARKET WIRE Simply Wall St • 1d ago

Royalty Pharma (Nasdaq:RPRX) - Stock Analysis

Simply Wall St report covering Royalty Pharma plc (Class A) (RPRX) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🟡 MARKET WIRE Yahoo! Finance Canada • 1d ago

Royalty Pharma plc (RPRX) Stock Price, News, Quote & History

Yahoo! Finance Canada report covering Royalty Pharma plc (Class A) (RPRX) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🟡 MARKET WIRE Benzinga • 1d ago

If You Invested $1000 In Royalty Pharma Stock 15 Years Ago, You Would Have This Much Today

Benzinga report covering Royalty Pharma plc (Class A) (RPRX) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🟢 CATALYST MarketBeat • 1d ago

Royalty Pharma (NASDAQ:RPRX) Stock Jumps 3.3% - Here's Why

MarketBeat report covering Royalty Pharma plc (Class A) (RPRX) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🟡 MARKET WIRE Simply Wall St • 1d ago

Royalty Pharma (RPRX), Why Is It Back In The Spotlight?

Simply Wall St report covering Royalty Pharma plc (Class A) (RPRX) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🔴 RISK WATCH Yahoo • 3d ago

Zenas BioPharma Eyes Key Lupus and IL-17 Data as Obexelimab FDA Decision Nears

Zenas BioPharma (NASDAQ:ZBIO) outlined development plans for obexelimab in systemic lupus erythematosus (SLE) and ZB021, an investigational oral IL-17AA/AF inhibitor, during an R&D event ahead of clinical data expected l

Read Full Source ↗

🔥 THE ROAR PIT • LIVE COMMUNITY DEBATE 3 Active Posts & Replies

RPRX Bull vs. Bear Conversation Board — What's Your Call at $66.52?

🐂 67% BULLISH CONVICTION COMMUNITY TUG-OF-WAR ON RPRX 🐻 33% BEARISH CONVICTION

SI SiliconVal_Bull RQD DEBATE OPENER • Growth & Tech Investor 🐂 BULLISH 🎯 Target: $78.60 (+17.0%)

📌 Pinned Debate

Institutional accumulation (18/20 whale-flow pillar) and a strong forensic balance sheet (Piotroski F 8/9, Altman Z 2.9) support the Ro

The street is overcomplicating Royalty Pharma plc (Class A) (RPRX). Institutional accumulation (18/20 whale-flow pillar) and a strong forensic balance sheet (Piotroski F 8/9, Altman Z 2.9) support the Roarable Buy rating.. With an RQD score of 76/100 (B+) and Forensic Balance Sheet at 14/20, any positive earnings surprise or guidance raise forces underweight funds to chase above $72.55.

CapAlloc_Nerd 🐂 BULL

@SkepticalCFA Fair point on 49.2x trailing P/E, but you're ignoring the forward operating leverage in Biotechnology: Pharmaceutical Preparations. If gross margin (0.0%) holds, EPS grows into the multiple faster than bears think.

SK SkepticalCFA RQD DEBATE OPENER • Fundamental Contrarian 🐻 BEARISH 🎯 Target: $51.73 (-23.0%)

Spot @ $67.18

A P/E (TTM) of 49.2 and ROIC of 7% leave the valuation dependent on sustained cash generation, with net income declining from $1.13B

A P/E (TTM) of 49.2 and ROIC of 7% leave the valuation dependent on sustained cash generation, with net income declining from $1.13B to $770.9M over FY 2023–FY 2025.. Look at the math on RPRX: paying 49.2x trailing P/E for 7.0% ROIC and 65.6% operating margins leaves zero margin of safety if Biotechnology: Pharmaceutical Preparations demand softens. I'd wait for a retest of $59.12 before getting long.